Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.
MGMT-unmethylated Glioblastoma (GBM)|GBM
DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Radiation Therapy (RT)
1-year Overall Survival (OS), Survival rate is defined as the percentage of participants who survived at 1 year (from either the date of diagnosis or the start of treatment for a disease), 1 year
Median Overall Survival (OS), Median survival rate of evaluable participants will be reported in months of survival, 3 years|Median Progression Free Survival (PFS), The length of time during and after the treatment that a patient lives with the disease but it does not get worse., 3 years
This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.